Crispr Therapeutics AG vs JD.Com Inc — how do they compare? Crispr Therapeutics AG trades at $53.9 (market cap $5.23B), while JD.Com Inc trades at $31.44 (market cap $44.04B). The key difference: JD.Com Inc is far larger — about 8.4× Crispr Therapeutics AG's market cap, and JD.Com Inc pays a 3.13% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| CRSP | JD | |
|---|---|---|
Market Cap | $5.23B | $44.04B |
Sector | Health | Consumer Cyclical |
52-Week High | $76.78 | $36.17 |
52-Week Low | $44.34 | $25.19 |
Enterprise Value | $3.65B | $30.10B |
Dividend Yield | — | 3.13% |
Trailing returns across standard periods
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →JD.com is China's second-largest e-commerce company after Alibaba in terms of gross merchandise volume, offering a wide selection of authentic products at competitive prices, with speedy and reliable delivery. The company has built its own nationwide fulfilment infrastructure and last-mile delivery network, staffed by its own employees, which supports both its online direct sales, its online marketplace and omnichannel businesses.
Read more on JD →